Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

(2017) John M.S. Bartlett et al.   EUROPEAN JOURNAL OF CANCER

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline

(2017) Sukhbinder Dhesy-Thind et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Michael Gnant et al.   LANCET

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

(2015)   LANCET

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

(2014) M. Gnant et al.   ANNALS OF ONCOLOGY

Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo

(2014) P. D. Ottewell et al.   CLINICAL CANCER RESEARCH

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

(2014) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

(2014) Robert Coleman et al.   LANCET ONCOLOGY

Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer

(2014) Trisha F. Hue et al.   JAMA Internal Medicine

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

(2012) R. Coleman et al.   ANNALS OF ONCOLOGY

Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations

(2012) Peyman Hadji et al.   CANCER TREATMENT REVIEWS

Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo

(2012) H. K. Brown et al.   CLINICAL & EXPERIMENTAL METASTASIS

Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group

(2012) Peter C. Dubsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic Review of Bone Health in Older Women Treated with Aromatase Inhibitors for Early-Stage Breast Cancer

(2012) Taryn Becker et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

(2012) Alexander HG Paterson et al.   LANCET ONCOLOGY

Final 5-year results of Z-FAST trial

(2011) Adam M. Brufsky et al.   CANCER

Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature

(2011) Michael Gnant et al.   CANCER TREATMENT REVIEWS

Use of Bisphosphonates and Reduced Risk of Colorectal Cancer

(2011) Gad Rennert et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

(2011) Michael Gnant et al.   LANCET ONCOLOGY

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2011) Robert E. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class

(2010) Philippe Clézardin   BONE

Dosing of zoledronic acid throughout the treatment continuum in breast cancer

(2010) Peyman Hadji et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer

(2010) Chris R. Cardwell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism

(2010) Michael J. Rogers et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

(2010) Rebecca Aft et al.   LANCET ONCOLOGY

Tumor Self-Seeding by Circulating Cancer Cells

(2009) Mi-Young Kim et al.   CELL

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow--a long-term follow-up

(2008) I. J. Diel et al.   ANNALS OF ONCOLOGY

In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients

(2008) Daniele Santini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study

(2008) Vincent Launay-Vacher et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

(2008) Richard Eastell et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

(2008) Michael Gnant et al.   LANCET ONCOLOGY